Myocardial InjuryMICOLONNCT02150486
Myocardial Injury and Postoperative Complications
An observational study of Myocardial Injury, run by St. Antonius Hospital at 1 site in Netherlands.
Trial summary
To determine whether perioperative myocardial injury is associated with adverse outcome in patients scheduled for major abdominal surgery. Read more about this study
- Who is it for?
- Ages 45 years and older
- Conditions the study is for
- Myocardial Injury
- How many people
- 210 participants
- Where
- 1 siteNetherlands
- Study dates
- Jun 2012to Mar 2014
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: Patients scheduled for elective abdominal surgery at risk for coronary artery disease
Who may be able to join
- Patients > 45 years of age with 1 or more major cardiovascular risk factors: Congestive heart failure, peripheral artery disease (intermittent claudication, history of vascular surgery etc), diabetes mellitus type I or II, coronary artery disease (history of myocardial infarction, stable angina pectoris, history of ischemia or coronary artery disease on cardiac tests (electrocardiogram, scintigraphy, echocardiogram, coronary angiogram etc), cerebrovascular accident, renal insufficiency (creatinine > 150umol/l), aortic valve stenosis (valve area < 1 cm2) OR 2 or more minor cardiovascular risk factors: Age > 70, hypertension, high cholesterol, low functional capacity (4 metabolic equivalents or less), transient ischemic attack, chronic obstructive pulmonary disease AND undergoing abdominal surgery with an expected 30-day mortality rate > 2-3%: colorectal, gastric, pancreatic and liver surgery.
Who cannot join
- Age < 45 years of age, not scheduled for higher risk abdominal surgery, low cardiovascular risk profile.
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Postoperative Myocardial Injury and Non-cardiac Complications After Major Abdominal Surgery in Patients at Risk for Coronary Artery Disease
To determine whether perioperative myocardial injury is associated with adverse outcome in patients scheduled for major abdominal surgery.
Read the detailed description
Study design
The MICOLON study is a prospective, single-centre, observational cohort study on the association between 5th generation high sensitive cardiac troponin T levels and non-cardiac outcome after major abdominal surgery in patients at risk for coronary artery disease.
Patient eligibility
Patients are eligible to enter the study if they are scheduled to undergo elective major abdominal surgery with an expected postoperative mortality rate >3%, are aged 45 years or older and have at least one of the following major cardiac risk factors: diabetes mellitus, peripheral artery disease (i.e. intermittent claudication or history of vascular surgery except arteriovenous shunt and vein stripping procedures), history of hospitalization for congestive heart failure, history of myocardial infarction, stable angina pectoris, history of coronary artery bypass grafting or percutaneous coronary angioplasty, renal insufficiency (defined as preoperative creatinine >150 μmol/L), history of cerebral vascular event, aortic valve stenosis (defined as aortic valve area <1 cm2), atrial fibrillation, moderate or poor left ventricular function (defined as left ventricular ejection fraction <55%), or two of the following minor risk factors for coronary artery disease: age >70 years, hypertension, hypercholesterolemia, history of transient ischemic attack, chronic obstructive pulmonary disease, smoking or low functional capacity (capable of physical activity of 4 metabolic equivalents or less). Patients are excluded from study participation if they have no signed informed consent.
Study procedure
Patients eligible for the study are identified at the outpatient preoperative anesthesiology clinic. Patients are examined and screened for cardiac risk factors by an anesthesiology resident or a dedicated screening nurse. Results of preoperative laboratory tests, data on patient characteristics and preoperative use of cardiovascular drugs (i.e. statin, ß--blocker, platelet inhibitor, calcium antagonists, angiotensin-converting enzyme inhibitor and angiotensine receptor blocker) were noted. Prior to any study procedure written informed consent is obtained from all patients. During the study period blood is collected for plasma troponin T measurements after induction of general anesthesia (baseline) and on the 1st, 3rd and 7th postoperative day. All plasma samples are frozen and stored at -20°C at the hospital's laboratory until analysis. Cardiac troponin T batch analysis is performed every 3 weeks with the use of 5th generation Elecsys Troponin T high sensitive assay on an automated Cobas 6000 platform (Roche Diagnostics, Germany). The limit of detection of this high sensitive assay was determined at 3 ng/L with a 99th percentile upper reference limit of 14 ng/L. In addition, plasma creatinine levels are measured in each sample with an enzymatic method on the same automated platform (Roche Diagnostics, Germany). An estimated glomerular filtration rate is calculated from plasma creatinine values using the Modification of Diet in Renal Disease formula. During the entire study period daily routine quality control samples for troponin and creatinine ensure comparable patient data across different reagent lots. After analysis the samples are stored at -80°C.
Surgical procedures are performed under general anesthesia or a combination of general and epidural anesthesia. Anesthesia management is left to the discretion of the attending anesthesiologist. According to hospital protocol, patients scheduled for gastric-esophageal, pancreatic or hepatic surgery and patients aged ≥80 or with an American Association of Anesthesiologists physical status classification system ≥3 will be admitted to an intensive care unit postoperatively for at least 24 hours. To improve postoperative recovery all patients are treated according to the current Enhanced Recovery After Surgery guidelines.
During the postoperative period research personnel performs patient visits, reviews medical charts and notes complications. At thirty days after surgery troponin results are reported to the researchers and a follow-up telephone interview is performed if patients are discharged from the hospital at that time. Patients will be asked if a medical complication has occurred since their discharge from the hospital. If so, medical details are retrieved from their treating physicians. Information from routine postoperative clinic visits is used if patients can not be reached by telephone. Noted endpoints are judged by an event committee, that is blinded for troponin results.
Endpoint definition
Primary parameter of the study is postoperative myocardial injury at day 1, 3 or 7. Secondary parameters are met by the occurrence of any of the following non-cardiac events within 30 days after surgery: mortality - defined as death without cardiovascular origin; sepsis - defined as systemic inflammatory response syndrome (SIRS) in response to a proven or suspected microbial infection; pneumonia - defined as purulent sputum or isolation of a pathogen from sputum culture or blood culture and clinical symptoms (e.g. dyspnea, fever, cough) or a consolidation or pleural effusion on chest radiograph; respiratory failure - defined as non-cardiac hypoxia or hypercapnia leading to ICU (re)admission for respiratory support (e.g. (non)invasive ventilation or high concentration oxygen therapy); anastomotic dehiscence - defined as presence of luminal contents through drain or wound site causing local inflammation or SIRS, or leak detected on imaging studies in combination with clinical signs of SIRS; intestinal ischemia - defined as signs of superficial or transmural bowel ischemia on imaging studies and clinical symptoms (e.g. abdominal pain or tenderness) or SIRS; wound infection - purulent drainage from superficial incision or deliberate opening of superficial incision by surgeon and clinical signs of local inflammation (e.g. pain, tenderness, swelling, redness); bleeding - defined as abnormal postoperative bleeding needing surgical (i.e. re-operation) or endovascular (i.e. coiling) treatment. Other study parameters were length of hospital stay and in-hospital mortality.
- Conditions
- Myocardial Injury
What is being measured
The primary outcome is the main question the study is designed to answer.
Postoperative myocardial injury
high sensitive troponin elevation at day 1, 3 or 7 after surgery
Measured: 7 days
Secondary outcomes (1)
Complication
wound infection, pneumonia, anastomotic dehiscence, sepsis, respiratory insufficiency, bleeding, intestinal ischemia, death.
Measured: 30-days
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted30 May 2014 (estimated)
- Study startJun 2012
- Primary completionFeb 2014
- Study completionMar 2014
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (2)Papers the sponsor has linked to this study.
- Other trials for Myocardial InjuryStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 210 participants (actual)
Sponsor and investigators
- Lead sponsor
- St. Antonius Hospital
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, dr. P. Noordzij, St. Antonius Hospital
- Investigators
- Peter Noordzij, MD, Principal investigator, St. Antonius Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT02150486
- Sponsor's protocol ID
- NL39172.100.11
- Acronym
- MICOLON
- Status last verified
- May 2025
- First submitted
- 27 May 2014
- Last updated
- 15 May 2025
- Results posted
- No
- Data monitoring committee
- No
Publications
Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators; Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, Villar JC, Wang CY, Garutti RI, Jacka MJ, Sigamani A, Srinathan S, Biccard BM, Chow CK, Abraham V, Tiboni M, Pettit S, Szczeklik W, Lurati Buse G, Botto F, Guyatt G, Heels-Ansdell D, Sessler DI, Thorlund K, Garg AX, Mrkobrada M, Thomas S, Rodseth RN, Pearse RM, Thabane L, McQueen MJ, VanHelder T, Bhandari M, Bosch J, Kurz A, Polanczyk C, Malaga G, Nagele P, Le Manach Y, Leuwer M, Yusuf S. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2012 Jun 6;307(21):2295-304. doi: 10.1001/jama.2012.5502.
PubMed 22706835Noordzij PG, van Geffen O, Dijkstra IM, Boerma D, Meinders AJ, Rettig TC, Eefting FD, van Loon D, van de Garde EM, van Dongen EP. High-sensitive cardiac troponin T measurements in prediction of non-cardiac complications after major abdominal surgery. Br J Anaesth. 2015 Jun;114(6):909-18. doi: 10.1093/bja/aev027. Epub 2015 Mar 3.
PubMed 25740400
Study at a glance
From the registry record, last updated by the sponsor on 15 May 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Postoperative Myocardial Injury and Non-cardiac Complications After Major Abdominal Surgery in Patients at Risk for Coronary Artery Disease
- ClinicalTrials.gov ID
- NCT02150486
- Acronym / sponsor ID
- MICOLON / NL39172.100.11
- Conditions
- Myocardial Injury
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 210 participants (actual)
- Lead sponsor
- St. Antonius HospitalUniversity, hospital or other
- Study start
- Jun 2012
- Primary completion
- Feb 2014 (actual)
- Study completion
- Mar 2014 (actual)
- First posted
- 30 May 2014 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
To determine whether perioperative myocardial injury is associated with adverse outcome in patients scheduled for major abdominal surgery.
Detailed description
Study design
The MICOLON study is a prospective, single-centre, observational cohort study on the association between 5th generation high sensitive cardiac troponin T levels and non-cardiac outcome after major abdominal surgery in patients at risk for coronary artery disease.
Patient eligibility
Patients are eligible to enter the study if they are scheduled to undergo elective major abdominal surgery with an expected postoperative mortality rate >3%, are aged 45 years or older and have at least one of the following major cardiac risk factors: diabetes mellitus, peripheral artery disease (i.e. intermittent claudication or history of vascular surgery except arteriovenous shunt and vein stripping procedures), history of hospitalization for congestive heart failure, history of myocardial infarction, stable angina pectoris, history of coronary artery bypass grafting or percutaneous coronary angioplasty, renal insufficiency (defined as preoperative creatinine >150 μmol/L), history of cerebral vascular event, aortic valve stenosis (defined as aortic valve area <1 cm2), atrial fibrillation, moderate or poor left ventricular function (defined as left ventricular ejection fraction <55%), or two of the following minor risk factors for coronary artery disease: age >70 years, hypertension, hypercholesterolemia, history of transient ischemic attack, chronic obstructive pulmonary disease, smoking or low functional capacity (capable of physical activity of 4 metabolic equivalents or less). Patients are excluded from study participation if they have no signed informed consent.
Study procedure
Patients eligible for the study are identified at the outpatient preoperative anesthesiology clinic. Patients are examined and screened for cardiac risk factors by an anesthesiology resident or a dedicated screening nurse. Results of preoperative laboratory tests, data on patient characteristics and preoperative use of cardiovascular drugs (i.e. statin, ß--blocker, platelet inhibitor, calcium antagonists, angiotensin-converting enzyme inhibitor and angiotensine receptor blocker) were noted. Prior to any study procedure written informed consent is obtained from all patients. During the study period blood is collected for plasma troponin T measurements after induction of general anesthesia (baseline) and on the 1st, 3rd and 7th postoperative day. All plasma samples are frozen and stored at -20°C at the hospital's laboratory until analysis. Cardiac troponin T batch analysis is performed every 3 weeks with the use of 5th generation Elecsys Troponin T high sensitive assay on an automated Cobas 6000 platform (Roche Diagnostics, Germany). The limit of detection of this high sensitive assay was determined at 3 ng/L with a 99th percentile upper reference limit of 14 ng/L. In addition, plasma creatinine levels are measured in each sample with an enzymatic method on the same automated platform (Roche Diagnostics, Germany). An estimated glomerular filtration rate is calculated from plasma creatinine values using the Modification of Diet in Renal Disease formula. During the entire study period daily routine quality control samples for troponin and creatinine ensure comparable patient data across different reagent lots. After analysis the samples are stored at -80°C.
Surgical procedures are performed under general anesthesia or a combination of general and epidural anesthesia. Anesthesia management is left to the discretion of the attending anesthesiologist. According to hospital protocol, patients scheduled for gastric-esophageal, pancreatic or hepatic surgery and patients aged ≥80 or with an American Association of Anesthesiologists physical status classification system ≥3 will be admitted to an intensive care unit postoperatively for at least 24 hours. To improve postoperative recovery all patients are treated according to the current Enhanced Recovery After Surgery guidelines.
During the postoperative period research personnel performs patient visits, reviews medical charts and notes complications. At thirty days after surgery troponin results are reported to the researchers and a follow-up telephone interview is performed if patients are discharged from the hospital at that time. Patients will be asked if a medical complication has occurred since their discharge from the hospital. If so, medical details are retrieved from their treating physicians. Information from routine postoperative clinic visits is used if patients can not be reached by telephone. Noted endpoints are judged by an event committee, that is blinded for troponin results.
Endpoint definition
Primary parameter of the study is postoperative myocardial injury at day 1, 3 or 7. Secondary parameters are met by the occurrence of any of the following non-cardiac events within 30 days after surgery: mortality - defined as death without cardiovascular origin; sepsis - defined as systemic inflammatory response syndrome (SIRS) in response to a proven or suspected microbial infection; pneumonia - defined as purulent sputum or isolation of a pathogen from sputum culture or blood culture and clinical symptoms (e.g. dyspnea, fever, cough) or a consolidation or pleural effusion on chest radiograph; respiratory failure - defined as non-cardiac hypoxia or hypercapnia leading to ICU (re)admission for respiratory support (e.g. (non)invasive ventilation or high concentration oxygen therapy); anastomotic dehiscence - defined as presence of luminal contents through drain or wound site causing local inflammation or SIRS, or leak detected on imaging studies in combination with clinical signs of SIRS; intestinal ischemia - defined as signs of superficial or transmural bowel ischemia on imaging studies and clinical symptoms (e.g. abdominal pain or tenderness) or SIRS; wound infection - purulent drainage from superficial incision or deliberate opening of superficial incision by surgeon and clinical signs of local inflammation (e.g. pain, tenderness, swelling, redness); bleeding - defined as abnormal postoperative bleeding needing surgical (i.e. re-operation) or endovascular (i.e. coiling) treatment. Other study parameters were length of hospital stay and in-hospital mortality.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 45 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- Patients scheduled for elective abdominal surgery at risk for coronary artery disease
Key inclusion criteria (1 listed)
- Patients > 45 years of age with 1 or more major cardiovascular risk factors: Congestive heart failure, peripheral artery disease (intermittent claudication, history of vascular surgery etc), diabetes mellitus type I or II, coronary artery disease (history of myocardial infarction, stable angina pectoris, history of ischemia or coronary artery disease on cardiac tests (electrocardiogram, scintigraphy, echocardiogram, coronary angiogram etc), cerebrovascular accident, renal insufficiency (creatinine > 150umol/l), aortic valve stenosis (valve area < 1 cm2) OR 2 or more minor cardiovascular risk factors: Age > 70, hypertension, high cholesterol, low functional capacity (4 metabolic equivalents or less), transient ischemic attack, chronic obstructive pulmonary disease AND undergoing abdominal surgery with an expected 30-day mortality rate > 2-3%: colorectal, gastric, pancreatic and liver surgery.
Key exclusion criteria (1 listed)
- Age < 45 years of age, not scheduled for higher risk abdominal surgery, low cardiovascular risk profile.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Postoperative myocardial injury
Time frame: 7 days
high sensitive troponin elevation at day 1, 3 or 7 after surgery
1 secondary outcome
Complication
Time frame: 30-days
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 15 May 2025.
- Background: PubMed 22706835Vascular Events In Noncardiac Surgery Patients Cohort Evaluation (VISION) Study Investigators; Devereaux PJ, Chan MT, Alonso-Coello P, Walsh M, Berwanger O, Villar JC, Wang CY, Garutti RI, Jacka MJ, Sigamani A, Srinathan S, Biccard BM, Chow CK, Abraham V, Tiboni M, Pettit S, Szczeklik W, Lurati Buse G, Botto F, Guyatt G, Heels-Ansdell D, Sessler DI, Thorlund K, Garg AX, Mrkobrada M, Thomas S, Rodseth RN, Pearse RM, Thabane L, McQueen MJ, VanHelder T, Bhandari M, Bosch J, Kurz A, Polanczyk C, Malaga G, Nagele P, Le Manach Y, Leuwer M, Yusuf S. Association between postoperative troponin levels and 30-day mortality among patients undergoing noncardiac surgery. JAMA. 2012 Jun 6;307(21):2295-304. doi: 10.1001/jama.2012.5502.
- Derived from this study: PubMed 25740400Noordzij PG, van Geffen O, Dijkstra IM, Boerma D, Meinders AJ, Rettig TC, Eefting FD, van Loon D, van de Garde EM, van Dongen EP. High-sensitive cardiac troponin T measurements in prediction of non-cardiac complications after major abdominal surgery. Br J Anaesth. 2015 Jun;114(6):909-18. doi: 10.1093/bja/aev027. Epub 2015 Mar 3.
Related trials for Myocardial Injury
Not yet recruitingPhase 4
Roxadustat and Myocardial Injury After Off-Pump Coronary Artery Bypass Surgery
Coronary Artery Disease, Coronary Artery Bypass Grafting
RecruitingPhase 2
Prevention of Reperfusion Injury Outcomes Through Effective Cardioprotection Targeting Myocardial Infarction
Myocardial Infarction, Reperfusion Injury
Not yet recruitingObservational study
PAtient Similarity for Decision-Making in Prevention of Cardiovascular Toxicity (PACT): A Feasibility Study
Heart Failure, Coronary Artery Disease
Not yet recruitingPhase 2
Evaluating SGLT2 Inhibitors for the Reduction of No-Reflow Phenomenon in Patients Undergoing PCI
No Reflow Phenomenon, Reperfusion Injuries, Myocardial
RecruitingObservational study
Mechanisms of Myocardial Injury and Ischemia in Patients With Rapid Atrial Fibrillation
Atrial Fibrillation (AF)
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Peter Noordzij, MD principal investigator
St. Antonius Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Myocardial Injury, run by St. Antonius Hospital at 1 site in Netherlands.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 15 May 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Netherlands. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Postoperative myocardial injury (time frame: 7 days). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT02150486, which also lists 2 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 May 2025.